Clinical characteristic and survival outcomes of patients with advanced NSCLC according to KRAS mutational status in the French real-life ESME cohort.
Fiche publication
Date publication
juin 2024
Journal
ESMO open
Auteurs
Membres identifiés du Cancéropôle Est :
Dr CLEMENT-DUCHENE Christelle, Dr DEBIEUVRE Didier
Tous les auteurs :
Thomas QD, Quantin X, Lemercier P, Chouaid C, Schneider S, Filleron T, Remon-Masip J, Perol M, Debieuvre D, Audigier-Valette C, Justeau G, Loeb A, Hiret S, Clement-Duchene C, Dansin E, Stancu A, Pichon E, Bosquet L, Girard N, Du Rusquec P
Lien Pubmed
Résumé
The RAS/MEK signaling pathway is essential in carcinogenesis and frequently altered in non-small-cell lung cancer (NSCLC), notably by KRAS mutations (KRASm) that affect 25%-30% of non-squamous NSCLC. This study aims to explore the impact of KRASm subtypes on disease phenotype and survival outcomes.
Mots clés
KRAS mutational status, NSCLC, immunotherapy, prognosis, real life data
Référence
ESMO Open. 2024 06 3;9(6):103473